Photonews Logo Photonews logo
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Azad Jammu Kashmir
    • Balochistan
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
    IShowSpeed Daniel La Belle race
    Videos

    IShowSpeed Beats Daniel La Belle in 40-Meter Race, Hits 41M Subscribers

    June 24, 2025 2 Min Read
    Cardi B new single Outside
    Videos

    Cardi B’s ‘Outside’ Single Sparks Buzz Over Offset and Stefon Diggs

    June 20, 2025 2 Min Read
    Squid Game Season 3
    Videos

    Squid Game Season 3: Final Trailer Unveils Epic Plot

    June 14, 2025 2 Min Read
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Reading: US FDA approves ‘female Viagra’ with strong warning
PhotoNews Pakistan PhotoNews Pakistan
Font ResizerAa
Search
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Balochistan
    • Azad Jammu Kashmir
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Have an existing account? Sign In
Follow US
© 2022 Photonews. All Rights Reserved.
PhotoNews Pakistan > World > US FDA approves ‘female Viagra’ with strong warning
World

US FDA approves ‘female Viagra’ with strong warning

Web Desk
By Web Desk Published August 19, 2015 5 Min Read
Share
SHARE

The first drug to treat low sexual desire in women won approval from US health regulators on Tuesday, but with a warning about potentially dangerous low blood pressure and fainting side effects, especially when taken with alcohol.

The US Food and Drug Administration said the pink pill, to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be available through certified and specially trained health care professionals and pharmacies due to its safety issues.

Addyi, whose chemical name is flibanserin, is designed for premenopausal women whose lack of sexual desire causes distress. The condition is formally known as hypoactive sexual desire disorder, or HSDD.

The drug needs to be taken daily. Addyi has been nicknamed the “female Viagra” even though it does not work like Pfizer Inc’s blockbuster Viagra pill for men that in 1998 became the first approved drug for erectile dysfunction.

“This is the biggest breakthrough in women’s sexual health since the advent of ‘the Pill’” for contraception, The National Consumers League said in a statement.

“It validates (and) legitimizes female sexuality as an important component of health.”

But Public Citizen, a consumer watchdog group that testified against the drug earlier this year, predicted that Addyi will be pulled from the market within a few years because of “serious dangers to women, with little benefit” to them.

“Unfortunately, we haven’t heard the last of this drug.”

The FDA had twice rejected the Raleigh, North Carolina-based firm’s drug. But the latest decision comes after an advisory panel concluded in June it should be approved with strict measures in place to ensure patients are fully aware of the risks.

Sprout officials could not immediately be reached for comment.

The news sent shares of Palatin Technologies, which is creating a rival drug for HSDD, up about 30 per cent to $1.21 in extended trade.

Palatin’s experimental treatment called bremelanotide is now in late-stage trials and works differently from Addyi.

It attempts to activate certain brain pathways. Palatin in a statement late Tuesday said its drug, if approved, would only be taken as needed, not on a daily basis like Addyi, thereby providing women “greater control and flexibility in their treatment.”

Unlike Viagra, which affects blood flow to the genitals, Addyi is meant to activate sexual impulses in the brain.

It is similar to a class of other drugs known as selective serotonin reuptake inhibitors, or SSRI’s, that include antidepressants such as Prozac.

Women who took Addyi in a clinical study had an increase of about one sexually satisfying event per month compared with those taking a placebo.  Advocates claim that increase is meaningful. Critics say the small benefit is outweighed by the drug’s risks.

Severe side effects

Addyi will come with a prominent “boxed warning” about side effects, including among people with liver impairment or who take Addyi with alcohol or with medicines known as CYP3A4 inhibitors that include certain steroids.

Originally developed by Germany’s Boehringer Ingelheim under its chemical name flibanserin, it was first rejected by the FDA in 2010 after an advisory panel said the benefits did not outweigh the risks.

Sprout acquired the drug, conducted additional studies and resubmitted the application.  In 2013, the FDA rejected it again.

The rejection sparked a lobbying campaign by Sprout, aided by some women’s groups who accused the FDA of gender bias because it had approved Viagra for men – a charge the FDA vigorously rejected.

The FDA approved Addyi despite a rocky relationship in recent years with the founders of Sprout.

The chief executive of Sprout, Cindy Whitehead, co-founded the company with her husband Robert Whitehead in 2011 after selling another small drugmaker they had founded called Slate Pharmaceuticals which had received repeated warnings from the FDA about its marketing tactics. Slate marketed an implantable testosterone pellet for men with low levels of the male sexual hormone, called Testopel.

In one FDA warning letter, issued on March 24, 2010, the FDA said Slate had improperly inferred on its Testopel website and in a video that the testosterone product could help patients with depression, erectile dysfunction, diabetes and HIV.

The Whiteheads could not be reached for comment late on Tuesday about Addyi’s approval and their earlier encounters with the FDA.

Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Advertisement

HBL Saving Made Easy
HBL Saving Made Easy

Recent Posts

Sheikh Naim Qassem Hezbollah's Ashura Speech

Hezbollah’s Naim Qassem Defies Israeli Threats in Ashura Speech

Travis Kelce Taylor Swift Proposal

Travis Kelce Delays Taylor Swift Marriage Proposal to Focus on NFL Career

Reuters X Account India

Reuters’ X Account Withheld in India

Post Archives

More Popular from Photonews

Pakistan Terrorists North Waziristan
Khyber Pakhtunkhwa

Pak Army Eliminates 30 Terrorists at Pak-Afghan Border in North Waziristan

2 Min Read
Hyundai Creta Theft Delhi in 60 seconds
Offbeat

Thieves Hack Hyundai Creta’s Security System in 60 Seconds

2 Min Read
Back to the Future 40th
Entertainment

Back to the Future at 40: How It Shaped Pop Culture in 2025

2 Min Read
Top NewsWorld

US Bombing of Iran’s Fordow Nuclear Site Causes Severe Damage: Iranian FM

Iranian Foreign Minister Abbas Araqchi reported that U.S. airstrikes “seriously and heavily damaged” Iran’s Fordow nuclear…

July 2, 2025
Entertainment

Jurassic World Rebirth: Release Date, Plot, Cast, and Trailer Details for 2025

Jurassic World Rebirth, the seventh film in the iconic Jurassic Park franchise, is set to captivate…

July 2, 2025
Tech

Meta Launches Superintelligence Labs to Lead AI Innovation

On July 1, 2025, Meta CEO Mark Zuckerberg announced the creation of Meta Superintelligence Labs (MSL),…

July 1, 2025
Entertainment

Drake Disses LeBron James on New Track “What Did I Miss?” from ICEMAN Album

Drake has set the stage for his highly anticipated ICEMAN album with the surprise release of…

July 6, 2025
PhotoNews Pakistan

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

Categories

  • World
  • Pakistan
  • Punjab
  • Sindh
  • Khyber Pakhtunkhwa
  • Balochistan
  • Azad Jammu Kashmir

 

  • Top News
  • Business
  • Entertainment
  • Sports
  • Videos
  • Tech
  • Offbeat
  • Blog

© 2024 Phototnews
All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?